Healthtech

AI is gutting healthcare's administrative cost layer

The automation of prior authorization, medical coding, revenue cycle management, and clinical documentation has moved from pilot to platform scale. Companies like Coral (seed, Lightspeed-led), Ethermed, Parallel, Silna, Amperos, and Commure are each attacking distinct administrative bottlenecks with AI agents — and Commure now processes $25B in annual claims across 3,000+ care sites. The Carlyle acquisition of Knack RCM and EqualizeRCM, alongside PE firm Thoreau Group's ~$12B acquisition of Ensemble Health Partners, signals that incumbents and private equity recognize administrative AI as a durable infrastructure layer, not a feature. Ambient documentation leaders like Abridge — deployed at Mayo Clinic, Duke Health, and Johns Hopkins — and Athelas are entrenching at the EHR layer as sticky, mission-critical tooling.

The $8B Curium acquisition of Lantheus and Tempus AI's $1.7B purchase of Personalis signal that precision oncology and radiopharmaceuticals are entering a consolidation phase driven by scale advantages in data and distribution. Tempus AI, which already anchors oncology AI workflows, absorbs Personalis to deepen genomic sequencing capabilities. Meanwhile, ClearNote Health's noninvasive Avantect® tests for pancreatic and ovarian cancers — selected for the NCI Vanguard Study — and Triomics' OncoLLM for cancer center workflow automation represent the next layer of targets. Johnson & Johnson's $785M acquisition of Sail Biomedicines further underscores that large pharma is deploying M&A capital aggressively in adjacent therapeutic areas.

Why it matters · Oncology AI and diagnostics are entering a buyer's market for M&A, making late-stage oncology-focused startups with proprietary data assets highly attractive strategic targets for pharma and imaging conglomerates.

a16z's Bio + Health team is concentrating bets on companies rebuilding primary care delivery from the ground up with AI. Counsel Health — a full-stack, AI-native medical group pairing real doctors with proprietary medical AI — and Leona Health are both backed by a16z Bio + Health alongside Hippocratic AI, suggesting a coordinated thesis around AI-scaled clinical capacity. Hippocratic AI has now completed over 115 million clinical patient interactions at a $3.5B valuation, validating that AI agents can handle non-diagnostic patient-facing workflows at scale. Nolla Health's vertically integrated AI doctor model — combining proprietary models with clinician-in-the-loop oversight — represents the next iteration of this archetype.

Why it matters · Full-stack AI health companies that own both the clinical model and patient relationship are positioning to become the primary care layer for underserved populations, threatening incumbents from GPP to telehealth.

Procter & Gamble's $3.8B acquisition of Thorne — a premium vitamin and supplement brand backed by L Catterton — is the clearest signal yet that consumer health brands commanding loyalty through quality positioning attract strategic premiums from CPG giants. This follows the broader category dynamic evidenced by Mary Ruth's liquid vitamin empire and Roe Nutrition's revenue growth through form-factor innovation. In wearables, Oura's confidential IPO filing and WHOOP's $3.6B valuation bracket a market where Garmin's new CIRQA Smart Band (118 Product Hunt upvotes) competes without a subscription model. Cal AI's $50-100M exit further illustrates how consumer health apps with viral distribution can achieve outsized outcomes.

Why it matters · CPG strategics are now paying 8-10x revenue multiples for premium consumer health brands, setting a high exit floor that will attract more DTC health founders and their investors.

Multiple companies are now raising dedicated capital to serve aging populations — a market signal that eldercare is graduating from a feature of general healthtech into a standalone investment thesis. Hera (AI-powered elder care coordination), Baba (dedicated human advocates plus AI proactive monitoring for seniors), and NewDays (AI companion for older adults) are each building distinct wedges into a market defined by complexity, caregiver scarcity, and massive unmet need. Lucis, a preventive health platform analyzing 110+ blood biomarkers with General Catalyst and Y Combinator backing, addresses the longevity optimization segment of the same demographic trend. Generation Lab's longevity diagnostics using biometrics to measure biological age further reinforces that investor attention is crystallizing around the entire aging lifecycle.

Why it matters · With eldercare demand structurally outpacing human caregiver supply, AI-native platforms that scale care coordination or preventive health will capture a disproportionate share of the largest and fastest-growing demographic in healthcare spending.